Selected article for: "acid bacteria and acute respiratory syndrome"
Author: Villena, Julio; Li, Chang; Vizoso-Pinto, Maria Guadalupe; Sacur, Jacinto; Ren, Linzhu; Kitazawa, Haruki
Title: Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines
  • Cord-id: k22lhyau
  • Document date: 2021_3_26
    • ID: k22lhyau
    Snippet: The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms inv
    Document: The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms involved in the improvement of mucosal antiviral defenses by beneficial Lactiplantibacillus plantarum strains, (b) the systems for the expression of heterologous proteins in L. plantarum and (c) the successful expressions of viral antigens in L. plantarum that were capable of inducing protective immune responses in the gut and the respiratory tract after their oral administration. The ability of L. plantarum to express viral antigens, including the spike protein of SARS-CoV-2 and its capacity to differentially modulate the innate and adaptive immune responses in both the intestinal and respiratory mucosa after its oral administration, indicates the potential of this LAB to be used in the development of a mucosal COVID-19 vaccine.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • academic scientific and acute respiratory syndrome: 1, 2
    • academic scientific and acute respiratory syndrome coronavirus: 1, 2
    • accessory cell and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • accessory cell and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • acid bacteria and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • acid bacteria and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • acid base vaccine and acute respiratory syndrome: 1
    • activate immune cell and acute respiratory syndrome: 1
    • activate immune cell and acute respiratory syndrome coronavirus: 1
    • activate immune cell and adaptive immune response: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive immune response impair: 1
    • acute respiratory syndrome coronavirus and adaptive immune response impair: 1